Sanofi SA (SNY)

43.16
0.38 0.87
NYSE : Health Care
Prev Close 43.54
Open 43.12
Day Low/High 43.06 / 43.33
52 Wk Low/High 36.81 / 44.50
Volume 1.81M
Avg Volume 1.87M
Exchange NYSE
Shares Outstanding 2.57B
Market Cap 112.08B
EPS 1.80
P/E Ratio 23.41
Div & Yield 1.66 (3.80%)

Latest News

DexCom Is a Great Healthcare Stock to Buy Now

DexCom Is a Great Healthcare Stock to Buy Now

The continuous glucose monitor maker is an excellent growth opportunity.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Mylan Shares Unchanged as Kaleo Releases EpiPen Competitor

Mylan Shares Unchanged as Kaleo Releases EpiPen Competitor

The Auvi-Q was released Feb. 14, but it's unclear whether patients will break up with their current option, EpiPen, for something new.

Biotech Tesaro Climbs on Takeout Reports

Biotech Tesaro Climbs on Takeout Reports

The company's shares were up 14% on rumors that it is working with investment banks to consider a sale.

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Biopharma's reticence suggests that fear of Trump's tweets and threats to limit drug pricing (and cut into profits) has stopped biotech companies from standing up for what's right.

Hagens Berman: Insulin Manufacturers Hit With Class-Action Lawsuit Over Drug Price Inflation Scheme And RICO Violations - Time To Break Up The Insulin Racket

Hagens Berman: Insulin Manufacturers Hit With Class-Action Lawsuit Over Drug Price Inflation Scheme And RICO Violations - Time To Break Up The Insulin Racket

People living with diabetes have filed a groundbreaking class-action lawsuit against the three makers of analog insulin drug products - Sanofi, Novo Nordisk and Eli Lilly - for exponentially raising consumer insulin prices...

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

Express Scripts, Cigna Opt Out of Paying for EpiPen Competitor Auvi-Q

Express Scripts, Cigna Opt Out of Paying for EpiPen Competitor Auvi-Q

It's unclear how much of the hefty $4,500 price pharmacy benefit managers or insurers will agree to pay to keep Auvi-Q free for most patients.

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Other movers included Mannkind, Perrigo and Bristol-Myers Squibb.

Regeneron Pharmaceuticals Could Be Ready to Rebound

Regeneron Pharmaceuticals Could Be Ready to Rebound

Regeneron has faced a lower stock price and patent wrangling. But the stock could be ready to rise again.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

5 Rocket Stocks for 2017 -- Amgen, eBay, More

5 Rocket Stocks for 2017 -- Amgen, eBay, More

These stocks are showing short-term gain catalysts and longer-term growth potential. Here's how to trade them.

Here's Why Teva Shares Are Plummeting

Here's Why Teva Shares Are Plummeting

Shares fall on worse-than-expected guidance. It was not a good day for Teva Pharmaceuticals.

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.

Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View

Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View

The Medicines Company, Alder also see share boosts on favorable implications. Jim Cramer weighs in on the implications for Amgen investors.

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.

5 Things You Must Know Before the Market Opens Friday

5 Things You Must Know Before the Market Opens Friday

U.S. stock futures trade slightly lower Friday ahead of the U.S. jobs report for December, the last under the Obama presidency.

Sanofi Investors Have Worst Day in Six Months

Sanofi Investors Have Worst Day in Six Months

Praluent Infringes on Amgen's patents for rival drug, Repatha, a ruling says.

After Stunning Loss to Amgen in Patent Case, Regeneron Plans to Join Sanofi in Appeal

After Stunning Loss to Amgen in Patent Case, Regeneron Plans to Join Sanofi in Appeal

A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.

European Stocks Open Lower as Investors Prep for U.S. Jobs Report

European Stocks Open Lower as Investors Prep for U.S. Jobs Report

European shares open with a defensive tone ahead of U.S. December nonfarm payrolls; Sanofi slumps on the Praluent injunction.

(Graphic: Business Wire)

(Graphic: Business Wire)

Sanofi and Boehringer Ingelheim confirmed today that the strategic transaction signed in June 2016, which consists of an exchange of Sanofi's animal health business (Merial) and Boehringer Ingelheim's consumer...

Actelion's Fate May Rest on Structure, Not Price, as Clozel Holds Firm

Actelion's Fate May Rest on Structure, Not Price, as Clozel Holds Firm

Actelion's CEO has held control at the company he founded, but its largest shareholder has ties with Johnson & Johnson.

5 Things You Must Know Before the Market Opens Thursday

5 Things You Must Know Before the Market Opens Thursday

U.S. stock futures post slight losses as investors await data on U.S. growth and durable goods; Carl Icahn is named special adviser to President-elect Donald Trump on overhauling federal regulations.

Actelion Hits Record High After Confirming Exclusive Talks With Johnson & Johnson

Actelion Hits Record High After Confirming Exclusive Talks With Johnson & Johnson

Shares in the biotech firm hit a record high Thursday after confirming 'exclusive' talks with Johnson & Johnson.

European Stocks Drift Lower in Holiday-Thinned Trading

European Stocks Drift Lower in Holiday-Thinned Trading

European stocks are likely to post modest losses Thursday as a slower holiday trading pace takes over regional markets.